Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.48 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.48 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.48 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.48 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.48 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.48 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097734 | 0.87 | GCGR (0.51) | KMT2ASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL4091869 | 0.86 | ABCG2 (0.46) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4082063 | 0.86 | GCGR (0.51) | SMN1; SMN2RAB9ANPC1ADCY6ADCY3 | |
| SCHEMBL4088384 | 0.86 | GCGR (0.62) | SMN1; SMN2RAB9ANPC1ADCY6ADCY3 | |
| SCHEMBL4086516 | 0.85 | GCGR (0.50) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4085583 | 0.85 | GCGR (0.50) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4091878 | 0.85 | RAB9A (0.45) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4081695 | 0.85 | NR1H4 (0.52) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL4086902 | 0.84 | NR1H4 (0.53) | MEN1KMT2AMAPTSMN1; SMN2RAB9A | |
| SCHEMBL4091978 | 0.84 | GCGR (0.51) | MEN1KMT2ALMNARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MEN1 2079/4885KMT2A 3304/4885MAPT 4379/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | MEN1 2079/4885KMT2A 3304/4885MAPT 4379/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | MEN1 2079/4885KMT2A 3304/4885MAPT 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.